Kaposi Sarcoma Pipeline Report, H1 2020 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

DUBLIN, March 24, 2020 /PRNewswire/ -- The "Kaposi Sarcoma - Pipeline Review, H1 2020" report has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 4, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

Key Topics Covered

1. Introduction
2. Kaposi Sarcoma - Overview
3. Kaposi Sarcoma - Therapeutics Development
4. Kaposi Sarcoma - Therapeutics Assessment
5. Kaposi Sarcoma - Companies Involved in Therapeutics Development
6. Kaposi Sarcoma - Drug Profiles
7. Kaposi Sarcoma - Dormant Projects
8. Kaposi Sarcoma - Discontinued Products
9. Kaposi Sarcoma - Product Development Milestones

Companies Mentioned

• Aphios Corp
• Bristol-Myers Squibb Co
• Cannabis Science Inc
• Cello Therapeutics Inc
• Genexine Inc
• LATITUDE Pharmaceuticals Inc
• LipoSeuticals Inc
• Merck & Co Inc
• Nammi Therapeutics Inc
• Ono Pharmaceutical Co Ltd
• Tumorend LLC
• VasGene Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/a4ss95

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/kaposi-sarcoma-pipeline-report-h1-2020---analysis-by-stage-of-development-drug-target-mechanism-of-action-route-of-administration-and-molecule-type-301029178.html

SOURCE Research and Markets